EUCTR2005-003434-18-IT进行中（未招募）1 期
Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin PLD, Caelyx, Doxil for Women age 66 years or older with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a Standard Chemotherapy Regimen
IBCSG0 个研究点目标入组 77 人开始时间: 2006年11月30日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 77
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a Standard Chemotherapy Regimen” - Chemotherapy Adjuvant Study for women at advanced Age (CASA)Older women (66 years of age or older) with histologically proven, resected breast cancer. The disease must be classified as endocrine nonresponsive and patients must not be candidates for endocrine therapy or for an adjuvant chemotherapy program which includes a standard” anthracycline-containing chemotherapy regimen.MedDRA version: 8.1Level: LLTClassification code 10006188Term: Breast cancer female NOSEUCTR2005-003434-18-FRInternational Breast Cancer Study Group (IBCSG)77
已完成
3 期
IBCSG 32-05 / BIG 1-05 - Chemotherapy Adjuvant Study for women at advanced ageCancer - BreastBreast CancerACTRN12606000077561Australian New Zealand Breast Cancer Trials Group1,296
进行中（未招募）
不适用
Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a Standard Chemotherapy Regimen” - Chemotherapy Adjuvant Study for women at advanced Age (CASA)Older women (66 years of age or older) with histologically proven, resected breast cancer. The disease must be classified as endocrine nonresponsive and patients must not be candidates for endocrine therapy or for an adjuvant chemotherapy program which includes a standard” anthracycline-containing chemotherapy regimen.MedDRA version: 8.1Level: LLTClassification code 10006188Term: Breast cancer female NOSEUCTR2005-003434-18-BEInternational Breast Cancer Study Group (IBCSG)1,296
进行中（未招募）
不适用
Phase III Trials Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a Standard Chemotherapy Regimen” - Chemotherapy Adjuvant Study for women at advanced Age (CASA)Older women (66 years of age or older) with histologically proven, resected breast cancer. The disease must be classified as endocrine nonresponsive and patients must not be candidates for endocrine therapy or for an adjuvant chemotherapy program which includes a standard” anthracycline-containing chemotherapy regimen.EUCTR2005-003434-18-HUInternational Breast Cancer Study Group (IBCSG)1,296
进行中（未招募）
不适用
Phase III Trials Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a Standard Chemotherapy Regimen” - Chemotherapy Adjuvant Study for women at advanced Age (CASA)Older women (66 years of age or older) with histologically proven, resected breast cancer. The disease must be classified as endocrine nonresponsive and patients must not be candidates for endocrine therapy or for an adjuvant chemotherapy program which includes a standard” anthracycline-containing chemotherapy regimen.EUCTR2005-003434-18-SIInternational Breast Cancer Study Group (IBCSG)1,296